ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

cebranopadol

Also written as “GRT6005”, “Cebranopadol” and “Cebranopadol 600 µg”.

Its studies are mostly in Pain · Chronic Pain · Acute Pain · Substance-Related Disorders · Osteoarthritis, led by 2 companies.

Drug pageCebranopadol: every studyAll 18 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Oct 7, 201318 company-led studies, 2 open or runningNext primary completion: Jan 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Tris Pharmaits history only160 open or runningphase 3since Oct 7, 2013Mar 24, 2009none ahead
Adneuris Therapeutics22 open or runningphase 3since Sep 22, 2026Sep 22, 2026Jan 2027phase 3 · NCT07845071

Also a collaborator on its studies: AbbVie.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Adneuris Therapeutics only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 22, 2026First study: phase 3 study in PainFirst studyNCT07845071 · 160 planned · United States
  2. Oct 8, 2026Phase 2 study in Chronic PainNCT07874620 · 45 planned · United States

Ahead

  1. Jan 2027Primary completion: phase 3 study in PainNCT07845071
  2. Mar 2027Primary completion: phase 2 study in Chronic PainNCT07874620

TargetBeta

“An orally available benzenoid that acts as an opioid peptide receptor agonist for the nociceptin/orphanin FQ peptide receptor (opioid receptor like -1; OPRL1; ORL-1; NOP; kappa-type 3 opioid receptor) and the classical opioid receptors, mu, delta and kappa, ”NCIt, by rule
“Nociceptin receptor agonist; Opioid receptors; mu/kappa/delta agonist”ChEMBL 37, by rule

Studies

All 2 Adneuris Therapeutics leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07874620Chronic Pain · United States2RecruitingMar 202745
NCT07845071Pain · United States3RecruitingJan 2027160

How it is read

Names in the registry

  • “GRT6005”, 8 entries
  • “Cebranopadol”, 5 entries
  • “Cebranopadol 600 µg”, 3 entries
  • “Cebranopadol 400 ug”, 2 entries
  • “Cebranopadol 1000 µg”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.